Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study
出版年份 2020 全文链接
标题
Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study
作者
关键词
Gemcitabine, Prospective study, Survival rate, Albumin-bound paclitaxel, Pancreatic cancer, Duration of therapy, Progression-free survival, Austria (MeSH)
出版物
EUROPEAN JOURNAL OF CANCER
Volume 143, Issue -, Pages 101-112
出版商
Elsevier BV
发表日期
2020-12-06
DOI
10.1016/j.ejca.2020.11.003
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer
- (2020) Satoshi Kobayashi et al. PANCREAS
- Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older
- (2020) Jonathan D. Mizrahi et al. PANCREATOLOGY
- Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
- (2020) Markus Kieler et al. Journal of Clinical Medicine
- Clinical outcomes of FOLFIRINOX and gemcitabine–nab paclitaxel for metastatic pancreatic cancer in the real world setting
- (2020) F. Franco et al. Clinical & Translational Oncology
- First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?
- (2020) Caterina Vivaldi et al. EUROPEAN JOURNAL OF CANCER
- Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
- (2019) Ursula M. Vogl et al. BMC CANCER
- The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients
- (2019) Utako Ishimoto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer
- (2019) Rikiya Hasegawa et al. International Journal of Clinical Oncology
- Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel
- (2019) Neha Papneja et al. PANCREAS
- Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer
- (2019) Roberto Petrioli et al. Journal of Geriatric Oncology
- Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience
- (2018) Danielle C. Glassman et al. BMC CANCER
- A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/− nab-paclitaxel in elderly pancreatic cancer patients (GrantPax)
- (2018) Johannes Betge et al. BMC CANCER
- Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
- (2018) Davendra P.S. Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2
- (2018) Teresa Macarulla et al. JOURNAL OF CLINICAL ONCOLOGY
- Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Margaret A. Tempero et al. Journal of the National Comprehensive Cancer Network
- NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
- (2016) Ferdinando De Vita et al. BMC CANCER
- Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
- (2016) E Gabriela Chiorean et al. BRITISH JOURNAL OF CANCER
- Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2016) Davendra P.S. Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis
- (2016) Daniel H. Ahn et al. Therapeutic Advances in Medical Oncology
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) M. Ducreux et al. ANNALS OF ONCOLOGY
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
- (2015) J. Tabernero et al. ONCOLOGIST
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
- (2015) D. Goldstein et al. JNCI-Journal of the National Cancer Institute
- European cancer mortality predictions for the year 2013
- (2013) M. Malvezzi et al. ANNALS OF ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started